Press Releases

 
Press Releases
  Date Title View
Jun 14, 2017
LEXINGTON, Mass., June 14, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehyde toxicity, today announced results from a Phase 2b clinical trial of topical ocular ADX-102 in patients with ...
PDF
Jun 13, 2017
LEXINGTON, Mass., June 13, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehyde toxicity, announced they will host a conference call and webcast on Wednesday, June 14, 2017 at 8:00 A.M. ED...
PDF
Jun 6, 2017
LEXINGTON, Mass., June 6, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today announced that it has enrolled the first patient into a Phase 2a clinical trial of topical ocular ADX...
PDF
May 17, 2017
LEXINGTON, MA -- (Marketwired) -- 05/17/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, presented the results of a randomized, multi-center, investigator-masked, comparator-controlled, paralle...
PDF
May 15, 2017
LEXINGTON, MA -- (Marketwired) -- 05/15/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today provided a corporate update and announced its financial results for the quarter ended March 31, 20...
PDF
May 8, 2017
LEXINGTON, MA -- (Marketwired) -- 05/08/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today announced it will provide a corporate update and issue financial results for the quarter ended Mar...
PDF
Apr 27, 2017
LEXINGTON, MA -- (Marketwired) -- 04/27/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species kno...
PDF
Apr 20, 2017
LEXINGTON, MA -- (Marketwired) -- 04/20/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotech company devoted to treating diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules, today announced that the United States Food and Drug Administration (...
PDF
Apr 18, 2017
LEXINGTON, MA -- (Marketwired) -- 04/18/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species kno...
PDF
Mar 30, 2017
LEXINGTON, MA -- (Marketwired) -- 03/30/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species kno...
PDF
Page: FirstPrevious
2
... NextLast